Perspective - (2023) Volume 10, Issue 1

Comprehensive study on Ciprofloxacin Bioavailability and Antibacterial Resistance

Yan Zhan*
Department of Surgery, Debre Tabor University, Debre Tabor, Ethiopia
*Correspondence: Yan Zhan, Department of Surgery, Debre Tabor University, Debre Tabor, Ethiopia, Email:

Received: Feb 14, 2023, Manuscript No. JEBMH-23-95778; Editor assigned: Feb 16, 2023, Pre QC No. JEBMH-23-95778 (PQ); Reviewed: Mar 03, 2023, QC No. JEBMH-23-95778; Revised: Mar 10, 2023, Manuscript No. JEBMH-23-95778 (R); Published: Mar 20, 2023, DOI: 10.18410/jebmh/2023/10/01/72

Citation: Zhan Y. Comprehensive Study on Ciprofloxacin Bioavailability and Antibacterial Resistance. J Evid Based Med Healthc 2023;10(01):1-1


Bioavailability studies are significant in pharmaceutical product development because they provide valuable information on how medications are absorbed and distributed in the body. Ciprofloxacin is an antibiotic that is used to treat various illnesses. They shall cover a bioavailability study on ciprofloxacin tablet formulation in this study.

Ciprofloxacin is a fluoroquinolone antibiotic with a broad spectrum of action that is used to treat bacterial infections such as respiratory, urinary tract, and skin diseases. The medication is available in a variety of forms, including tablets, injections, and topical treatments. Ciprofloxacin oral tablet formulation is frequently utilised due to its simplicity and ease of administration.

The amount of drug that reaches the systemic circulation after delivery of a drug product is referred to as bioavailability. Bioavailability studies are important in assessing a drug’s efficacy and safety. The goal of this study was to compare the bioavailability of ciprofloxacin in tablet form to the reference product.

Following ethical approval, the bioavailability study was undertaken on healthy human participants. A single-center, randomised, open-label, two-treatment, two-period crossover trial was planned. Ciprofloxacin is an antibiotic that is used to treat bacterial infections such as urinary tract infections, pneumonia, and skin infections. It is a fluoroquinolone antibiotic that works by inhibiting bacterial growth and reproduction. Ciprofloxacin is available in several dosage forms, including oral pills, intravenous injections, and ear and eye drops. In this study, they look at the bioavailability of four different ciprofloxacin tablet brands.

Bioavailability refers to the amount of an active drug that enters the systemic circulation and the rate at which it does so. The bioavailability of orally administered drugs such as ciprofloxacin is influenced by a variety of factors such as drug formulation, the presence of food in the stomach, and individual variations in drug metabolism. Bioavailability can be assessed using pharmacokinetic studies that measure the levels of the drug in the bloodstream over time.

The four ciprofloxacin tablet brands they compare in this post are Ciplox, Ciproflox, Cifran, and Ciprobid. These brands are produced by several firms and may differ in terms of formulation, manufacturing process, and excipients. A randomised crossover trial on healthy volunteers looked at the bioavailability of four ciprofloxacin tablet brands. Twelve healthy male volunteers were randomly assigned to receive a single dosage of each of the four brands of ciprofloxacin pills in a crossover design. Following drug administration, blood samples were collected at predetermined intervals to determine the concentration of ciprofloxacin in the bloodstream.

The findings of the study revealed that the bioavailability of the four ciprofloxacin tablet brands did not differ significantly. The area under the ciprofloxacin concen-tration-time curve, which quantifies the amount of drug in the systemic circulation, was the same across all four brands. The peak

Concentration of ciprofloxacin in the bloodstream was also consistent across all four brands. These data indicate that the four ciprofloxacin tablet brands have similar pharmacokinetic characteristics and should be equally effective in treating bacterial infections. However, it is important to remember that the study was conducted on healthy volunteers and may not accurately reflect ciprofloxacin bioavailability in patients with diseases.

Resistance to antibacterial drugs, notably quinolones, is one of the anti-infective agents that have attracted a lot of attention. One study, for example, revealed that the use of quinolones, like in most previous investigations, significantly increased the resistance of isolated E. coli from persons with Urinary Tract Infections (UTI). Ciprofloxacin, a second-generation fluoroquinolone, is one of the most regularly used quinolones. It has a broad spectrum of anti-infective activity and is well absorbed from the GI tract, with an absolute bioavailability of 70% to 85% after oral administration.